Sustained remission of symptoms and improved health-related quality of life in patients with cryopyrin-associated periodic syndrome treated with canakinumab: Results of a double-blind placebo-controlled randomized withdrawal study

Arthritis Research and Therapy

Volumn 13, Issue 6, 2011, Pages

  Koné Paut, Isabelle ^a   Lachmann, Helen J ^b   Kuemmerle Deschner, Jasmin B ^c   Hachulla, Eric ^d   Leslie, Kieron S ^e   Mouy, Richard ^f   Ferreira, Alberto ^g   Lheritier, Karine ^g   Patel, Neha ^g   Preiss, Ralph ^g   Hawkins, Philip N ^b  

^a BICÊTRE HOSPITAL   (France)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^c UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^d UNIV LILLE   (France)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f HÔPITAL NECKER ENFANTS MALADES   (France)

^g NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CANAKINUMAB; INTERLEUKIN 6; PLACEBO; SERUM AMYLOID A;

ADOLESCENT; ADULT; AGED; ARTHRALGIA; ARTICLE; CHILD; CINCA SYNDROME; CLINICAL ARTICLE; CLOSED ANGLE GLAUCOMA; CONJUNCTIVITIS; CONTROLLED STUDY; DISEASE ACTIVITY; DOUBLE BLIND PROCEDURE; DRUG RESPONSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FUNCTIONAL ASSESSMENT OF CHRONIC ILLNESS THERAPY FATIGUE; HEALTH ASSESSMENT QUESTIONNAIRE; HUMAN; INTRAOCULAR PRESSURE; MALE; MIGRAINE; MYALGIA; PHASE 3 CLINICAL TRIAL; PHYSICAL COMPONENT SUMMARY; PRESCHOOL CHILD; PROTEIN BLOOD LEVEL; QUALITY OF LIFE; QUALITY OF LIFE INDEX; RANDOMIZED CONTROLLED TRIAL; RASH; RELAPSE; REMISSION; SCHOOL CHILD; SEPSIS; SHORT FORM 36; SIDE EFFECT; UNILATERAL BLINDNESS; URINARY TRACT INFECTION; VERTIGO;

EID: 84855796483     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar3535     Document Type: Article

References (17)

1. Touitou I, Koné-Paut I. Autoinflammatory diseases. Best Pract Res Clin Rheumatol 2008, 22:811-829. 10.1016/j.berh.2008.08.009, 19028365.
2. Farasat S, Aksentijevich I, Toro JR. Autoinflammatory diseases: clinical and genetic advances. Arch Dermatol 2008, 144:392-402. 10.1001/archderm.144.3.392, 18347298.
3. Stych B, Dobrovolny D. Familial cold auto-inflammatory syndrome (FCAS): characterization of symptomatology and impact on patients' lives. Curr Med Res Opin 2008, 24:1577-1582. 10.1185/03007990802081543, 18423104.
4. Lachmann HJ, Lowe P, Felix SD, Rordorf C, Leslie K, Madhoo S, Wittkowski H, Bek S, Hartmann N, Bosset S, Hawkins PN, Jung T. In vivo regulation of interleukin 1beta in patients with cryopyrin-associated periodic syndromes. J Exp Med 2009, 206:1029-1036. 10.1084/jem.20082481, 2715040, 19364880.
5. Kuemmerle-Deschner J, Blank N, Roesler J, Ramos E, Lachmann HJ, Hoyer JD, Hiepe F, Hachulla E, Chaturvedi R, Rordorf C, Felix SD, Wright AM, Hawkins PN. Canakinumab (ACZ885), a new IL-1beta blocking monoclonal antibody, provides sustained remission in patients with cryopyrin associated periodic fever syndrome (CAPS): results of an open label phase II study. Ann Rheum Dis 2009, 68:366.
6. Lachmann HJ, Koné-Paut I, Kuemmerle-Deschner JB, Leslie KS, Hachulla E, Quartier P, Gitton X, Widmer A, Patel N, Hawkins PN. Use of canakinumab in the cryopyrin-associated periodic syndrome. N Engl J Med 2009, 360:2416-2425. 10.1056/NEJMoa0810787, 19494217.
7. Cella D, Yount S, Sorensen M, Chartash E, Sengupta N, Grober J. Validation of the Functional Assessment of Chronic Illness Therapy Fatigue Scale relative to other instrumentation in patients with rheumatoid arthritis. J Rheumatol 2005, 32:811-819.
8. Cella D, Lai JS, Chang CH, Peterman A, Slavin M. Fatigue in cancer patients compared with fatigue in the general United States population. Cancer 2002, 94:528-538. 10.1002/cncr.10245, 11900238.
9. Ware JE, Kosinski M, Keller S. SF-36 Physical and Mental Summary Scales: A User's Manual 1994, Boston: The Health Institute, New England Medical Center.
10. Ware JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36): I: conceptual framework and item selection. Med Care 1992, 30:473-483. 10.1097/00005650-199206000-00002, 1593914.
11. Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheum 1980, 23:137-145. 10.1002/art.1780230202, 7362664.
12. Landgraf JM, Maunsell E, Speechley KN, Bullinger M, Campbell S, Abetz L, Ware JE. Canadian-French, German and UK versions of the Child Health Questionnaire: methodology and preliminary item scaling results. Qual Life Res 1998, 7:433-445.
13. Goldbach-Mansky R, Dailey NJ, Canna SW, Gelabert A, Jones J, Rubin BI, Kim HJ, Brewer C, Zalewski C, Wiggs E, Hill S, Turner ML, Karp BI, Aksentijevich I, Pucino F, Penzak SR, Haverkamp MH, Stein L, Adams BS, Moore TL, Fuhlbrigge RC, Shaham B, Jarvis JN, O'Neil K, Vehe RK, Beitz LO, Gardner G, Hannan WP, Warren RW, Horn W, et al. Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition. N Engl J Med 2006, 355:581-592. 10.1056/NEJMoa055137, 16899778.
14. Leslie KS, Lachmann HJ, Bruning E, McGrath JA, Bybee A, Gallimore JR, Roberts PF, Woo P, Grattan CE, Hawkins PN. Phenotype, genotype, and sustained response to anakinra in 22 patients with autoinflammatory disease associated with CIAS-1/NALP3 mutations. Arch Dermatol 2006, 142:1591-1597. 10.1001/archderm.142.12.1591, 17178985.
15. Kuemmerle-Deschner JB, Hoyer J, Hachulla E, Chaturvedi R, Blank N, Hiepe F, Ferreira A, Felix SD, Wright AM, Jung T, Rordorf C. Effect of canakinumab (Ilaris, a fully human anti-IL-1 beta monoclonal antibody) on the health-related quality of life (HRQoL) in cryopyrin-associated periodic syndrome (CAPS) patients. http://www.blackwellpublishing.com/acrmeeting/abstract.asp?MeetingID=761&id=81107%202009.
16. Picavet HS, Hoeymans N. Health related quality of life in multiple musculoskeletal diseases: SF-36 and EQ-5D in the DMC3 study. Ann Rheum Dis 2004, 63:723-729. 10.1136/ard.2003.010769, 1755044, 15140781.
17. Lachmann HJ, Quartier P, So A, Hawkins PN. The emerging role of interleukin-1beta in autoinflammatory diseases. Arthritis Rheum 2010,